CVRx, Inc. (CVRX) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights several positive factors: improved revenue and gross margin guidance, the transition to a Category I CPT code, and strong confidence in future growth driven by sales rep productivity and center adoption. The Q&A section supports these positives, with management addressing concerns and outlining strategic initiatives. Despite some vague responses, the overall sentiment is optimistic, with potential catalysts like the FDA IDE application and the BENEFIT trial. The market is likely to react positively, predicting a 2% to 8% increase in stock price.
Key Financial Performance
Fourth Quarter Revenue $16 million, representing a growth of 4% year-over-year. The increase was driven by expansion into new sales territories, new accounts, and increased physician and patient awareness of Barostim.
Full Year Revenue $56.7 million, representing a growth of 10% year-over-year. The growth was attributed to investments in the commercial foundation, including strengthening the sales organization and refining the go-to-market approach.
Gross Profit $13.8 million for Q4 2025, an increase of $1.1 million or 8% year-over-year. The gross margin increased to 86% from 83% due to a higher average selling price and improved manufacturing efficiencies.
R&D Expenses $3 million for Q4 2025, an increase of $0.2 million or 7% year-over-year. The increase was primarily due to higher compensation expenses from increased headcount, partially offset by a decrease in clinical study expenses.
SG&A Expenses $22 million for Q4 2025, an increase of $1.8 million or 9% year-over-year. The increase was driven by higher compensation expenses due to increased headcount, as well as higher advertising and travel expenses, partially offset by lower consulting expenses.
Net Loss $11.9 million for Q4 2025, compared to $10.7 million in Q4 2024. The increase in net loss was due to higher operating expenses, including compensation, advertising, and travel costs.
Cash and Cash Equivalents $75.7 million as of December 31, 2025. Cash used in operating and investing activities was $40.8 million for the year, slightly higher than $40.5 million in 2024.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Barostim therapy: Barostim therapy improves exercise capacity and quality of life for heart failure patients. It addresses a critical unmet need for patients who remain symptomatic despite optimal medical therapy. The therapy is targeted at a prevalence pool of 339,000 patients, representing a $10.5 billion market opportunity.
Market opportunity: The prevalence-based addressable market for Barostim therapy is 339,000 patients, representing a $10.5 billion market opportunity. If the BENEFIT-HF trial is successful, the market could expand to 980,000 patients, representing a $30 billion opportunity.
Geographic expansion: Revenue in Europe increased by 10% to $1.1 million, with consistent sales territories. U.S. revenue grew by 4% to $14.9 million, driven by expansion into new sales territories and accounts.
Sales organization expansion: Expanded to 53 sales territories and 252 active implanting centers in the U.S., representing increases of 10% and 13%, respectively. Optimized field leadership structure and focused on high-potential accounts to drive adoption.
Reimbursement improvements: Transitioned to Category 1 CPT codes, effective January 1, 2026, improving patient access and reimbursement predictability. Medicare Advantage prior authorization approval rates improved from 31% in 2024 to 46% in 2025.
Clinical trial initiation: Initiated the BENEFIT-HF trial, a landmark randomized controlled trial to evaluate Barostim's impact on mortality and heart failure events. The trial could expand the addressable market significantly.
Strategic priorities: Focused on building a world-class sales organization, driving deep adoption in targeted centers, and reducing barriers to adoption. These efforts aim to create sustainable growth and improve access to Barostim therapy.
Long-term growth initiatives: The BENEFIT-HF trial, if successful, will triple the addressable market and enhance visibility and credibility in the heart failure community. Strengthened balance sheet with extended debt maturity and additional capital access.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Sales Force Transformation: The integration of new sales representatives has caused a near-term impact on growth as the team gains experience.
Barriers to Adoption: Challenges include patient access, therapy awareness, and clinical evidence. Although progress has been made, these barriers still hinder widespread adoption of Barostim therapy.
Reimbursement Challenges: Prior authorization denials and reimbursement predictability have been issues, though the transition to Category 1 CPT codes is expected to alleviate some of these challenges.
Clinical Trial Costs: The BENEFIT-HF trial is expected to have a net cash impact of $20 million to $30 million over 5 to 7 years, which could strain financial resources in the short term.
Operating Expenses: SG&A expenses increased by 9% year-over-year, driven by higher compensation, advertising, and travel expenses, which could pressure profitability.
Net Loss: The company reported a net loss of $11.9 million for Q4 2025, an increase from the $10.7 million loss in Q4 2024, indicating ongoing financial challenges.
Market Penetration: Despite a large addressable market, Barostim therapy remains less than 1% penetrated, highlighting significant room for growth but also the challenge of scaling adoption.
Economic Dependency on Medicare: The company’s reliance on Medicare coverage for the BENEFIT-HF trial and other initiatives could pose risks if policies or reimbursement rates change.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2026: The company expects total revenue between $63 million and $67 million for the full year of 2026.
Gross Margin Guidance for 2026: The company anticipates a gross margin between 84% and 86% for the full year of 2026.
Operating Expenses for 2026: Operating expenses are projected to be between $103 million and $107 million for the full year of 2026.
Q1 2026 Revenue Guidance: The company expects total revenue between $13.7 million and $14.7 million for the first quarter of 2026.
BENEFIT-HF Trial: The trial is expected to begin enrollment in Q2 2026 and will evaluate Barostim's impact on all-cause mortality and heart failure decompensation events. If successful, it could expand the addressable market from 339,000 patients to over 980,000 patients, tripling the market opportunity to approximately $30 billion.
Category 1 CPT Codes Impact: The transition to Category 1 CPT codes, effective January 1, 2026, is expected to improve patient access, reduce prior authorization denials, and enhance reimbursement predictability.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:On BENEFIT-HF, can you talk about the initial sites? Will these be new or existing commercial sites? And what's the overlap in the current indication? Will there be any revenue generation from the cases?
A:The recruitment of centers is early, with about 150 centers planned in the U.S. and a few in Germany. These centers are chosen based on their interest in the therapy and impact within the heart failure community. There will be a mix of centers already using Barostim and new ones. Regarding revenue, the trial design involves 2,500 randomizations, with 2/3 randomized to the device arm requiring implants. Approximately 1,600-1,700 devices are expected to be sold, reimbursed by Medicare or Medicare Advantage plans.
Q:The growth of active accounts in Q4 was low. How should we expect that to trend through 2026?
A:The sequential growth in Q4 was low due to the sales strategy of going deeper. The guidance for 2026 assumes adding around 3 active territories quarterly, with each managing 3-5 active implanting centers. This translates to high single-digit net account additions each quarter in 2026.
Q:Do you see any scenario where the BENEFIT-HF trial can be a tailwind for the core business while the trial is ongoing?
A:Yes, while significant revenue contribution from trial sites is not expected in the next year, the trial is expected to generate goodwill and credibility. It is the largest therapeutic device trial in heart failure, signaling confidence in the therapy and receiving positive feedback from the community.
Q:How has the Category 1 code, effective January 1, helped lower barriers to treatment?
A:The transition to the Category 1 code is progressing as expected. Efforts are focused on updating codes with payers and resubmitting prior authorizations. Early signs show payers who previously rejected prior authorizations are now approving them, and Medicare Advantage payers are approving at higher rates and more quickly.
Q:What gives you confidence in the 11%-18% top-line growth guidance for 2026?
A:The confidence comes from sequential growth observed from Q1 to Q4 in 2025 after a sales organization reset. Despite a seasonal dip expected from Q4 to Q1, sequential growth is anticipated throughout 2026, driven by increased productivity of sales reps hired in 2024 and 2025.
Q:What has been seen in getting sales reps up the productivity curve, and how should we think about the pace of improvement in 2026?
A:In 2025, efforts focused on hiring, onboarding, and training sales reps, growing active territories to 53 by year-end. Revenue units per territory increased, with more accounts achieving 1 implant per month. This momentum is expected to continue in 2026, with deeper adoption and workflow improvements at centers.
Q:Why is the gross margin guidance for 2026 set at 84%-86% despite recent quarters exceeding 86%?
A:The 2026 guidance is conservative, with U.S. ASPs expected around $31,000, consistent with 2025. Manufacturing efficiencies and capacity may reduce costs further, but these are not included in the initial guidance.
Q:What are the expectations for the BENEFIT trial cohort of patients and their response to the technology?
A:The HFmrEF population (ejection fraction 35-50) is expected to respond similarly to the HFrEF population (below 35), as both are neurohormonal disorders. The trial is designed to prove differences in survival, heart failure hospitalization, and quality of life for both populations.
Q:For the 2026 guidance, what is more important: activation of the right centers or same-store sales growth?
A:Driving deeper adoption at existing centers is the priority, with sales reps focusing on building network effects and increasing same-store sales. New territories and center activations will also contribute, but most growth is expected from deeper adoption.
Q:What do top accounts with high device implant rates have in common?
A:Top accounts have supportive leadership, multiple heart failure specialists, a pool of referring cardiologists, and redundant surgeons. These characteristics create a network effect and consistent utilization, forming the basis of the revised go-to-market strategy.
Q:What portion of the BENEFIT trial enrollment is expected to be outside the U.S. (OUS), and how will it be treated financially?
A:A very small number of centers will be outside the U.S., and these will not generate revenue. The trial is primarily U.S.-focused, leveraging Category B reimbursement.
Q:What is the path to profitability, and how is the business being managed to achieve it?
A:With $86 million in cash and access to $40 million in nondilutive capital, there is no immediate need for additional funding. Profitability will be driven by leveraging the productivity of existing sales reps, achieving faster top-line growth than SG&A growth, and continuing to add new territories.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the timeline for transitioning to the new Category 1 code and the exact impact on revenue. Additionally, while discussing the BENEFIT trial's impact on the core business, the response was vague about the extent of goodwill and credibility effects.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CMS approval
CVRx
Capital Partners
Category IDE
Category code
IDE coverage
Innovatus Capital
Medicare
access
adoption progress
adoption utilization
agreement Innovatus
approval Category
approval rate
balance sheet
capacity
compensation headcount
date
day
decrease interest
element
enrollment
facility
focus
foundation sale
fraction NT
increase unit
indication
landmark
market opportunity
population
prevalence
priority
proBNP level
quality life
representative
share loss
survival
therapy patient
transformation
validation
CVRX Transcript
CVRx, Inc. (CVRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-10
CVRx, Inc. (CVRX) Q1 2026 Earnings Call Transcript
Positive5-11
The earnings call highlights a 22% revenue growth in the U.S., exceeding expectations, and positive impacts from 2025 investments, indicating strong performance. However, the absence of shareholder return discussions and risks associated with forward-looking statements introduce some uncertainty. Overall, the positive growth and strategic investments outweigh the risks, suggesting a positive stock price reaction.
CVRx, Inc. (CVRX) Q4 2025 Earnings Call Transcript
Positive2-12
The earnings call highlights several positive factors: improved revenue and gross margin guidance, the transition to a Category I CPT code, and strong confidence in future growth driven by sales rep productivity and center adoption. The Q&A section supports these positives, with management addressing concerns and outlining strategic initiatives. Despite some vague responses, the overall sentiment is optimistic, with potential catalysts like the FDA IDE application and the BENEFIT trial. The market is likely to react positively, predicting a 2% to 8% increase in stock price.
CVRx, Inc. (CVRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
CVRX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
